{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:15:39Z","timestamp":1772129739816,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["HOME\/2014\/JDRU\/AG\/DRUG\/7082"],"award-info":[{"award-number":["HOME\/2014\/JDRU\/AG\/DRUG\/7082"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00213-019-05238-8","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T22:41:09Z","timestamp":1554849669000},"page":"2677-2685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis"],"prefix":"10.1007","volume":"236","author":[{"given":"Vincent T.","family":"Mensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"Vreeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Nordgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magi","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor M.","family":"Brunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"5238_CR1","doi-asserted-by":"publisher","unstructured":"Adamowicz P (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int, 261(July 2015), e5\u201310. \n                    https:\/\/doi.org\/10.1016\/j.forsciint.2016.02.024","DOI":"10.1016\/j.forsciint.2016.02.024"},{"issue":"3","key":"5238_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.psychres.2010.07.007","volume":"185","author":"A Agrawal","year":"2011","unstructured":"Agrawal A, Nurnberger JI, Lynskey MT, Bipolar Genome Study (2011) Cannabis involvement in individuals with bipolar disorder. Psychiatry Res 185(3):459\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.psychres.2010.07.007","journal-title":"Psychiatry Res"},{"issue":"10","key":"5238_CR3","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","volume":"42","author":"EG Altman","year":"1997","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM (1997) The Altman Self-Rating Mania Scale. Biol Psychiatry 42(10):948\u2013955. \n                    https:\/\/doi.org\/10.1016\/S0006-3223(96)00548-3","journal-title":"Biol Psychiatry"},{"issue":"6","key":"5238_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0006-3223(01)01065-4","volume":"50","author":"EG Altman","year":"2001","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM, McAllister T, Alahi P et al (2001) A comparative evaluation of three self-rating scales for acute mania. Biol Psychiatry 50(6):468\u2013471. \n                    https:\/\/doi.org\/10.1016\/S0006-3223(01)01065-4","journal-title":"Biol Psychiatry"},{"key":"5238_CR5","doi-asserted-by":"publisher","unstructured":"Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 19(4):23. \n                    https:\/\/doi.org\/10.1007\/s11920-017-0775-9","DOI":"10.1007\/s11920-017-0775-9"},{"issue":"August","key":"5238_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2014.04.038","volume":"165","author":"N Bally","year":"2014","unstructured":"Bally N, Zullino D, Aubry J-M (2014) Cannabis use and first manic episode. J Affect Disord 165(August):103\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.jad.2014.04.038","journal-title":"J Affect Disord"},{"key":"5238_CR7","doi-asserted-by":"publisher","unstructured":"Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL (2016) Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 30(12):1321\u20131330. \n                    https:\/\/doi.org\/10.1177\/0269881116658990","DOI":"10.1177\/0269881116658990"},{"issue":"1","key":"5238_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000081413","volume":"11","author":"AH Berman","year":"2005","unstructured":"Berman AH, Bergman H, Palmstierna T, Schlyter F (2005) Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res 11(1):22\u201331. \n                    https:\/\/doi.org\/10.1159\/000081413","journal-title":"Eur Addict Res"},{"key":"5238_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.addbeh.2016.07.005","volume":"63","author":"CE Blevins","year":"2016","unstructured":"Blevins CE, Banes KE, Stephens RS, Walker DD, Roffman RA (2016) A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: characteristics and treatment outcomes. Addict Behav 63:114\u2013119","journal-title":"Addict Behav"},{"issue":"4","key":"5238_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/13556210500350794","volume":"10","author":"MG Bossong","year":"2005","unstructured":"Bossong MG, Van Dijk JP, Niesink RJM (2005) Methylone and mCPP, two new drugs of abuse? Addict Biol 10(4):321\u2013323. \n                    https:\/\/doi.org\/10.1080\/13556210500350794","journal-title":"Addict Biol"},{"issue":"3","key":"5238_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/npp.2008.138","volume":"34","author":"MG Bossong","year":"2009","unstructured":"Bossong MG, van Berckel BNM, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JMA, Ramsey NF, Lammertsma AA, Kahn RS (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34(3):759\u2013766. \n                    https:\/\/doi.org\/10.1038\/npp.2008.138","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"5238_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1177\/0269881110378370","volume":"25","author":"TM Brunt","year":"2011","unstructured":"Brunt TM, Poortman A, Niesink RJ, van den Brink W (2011) Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25(11):1543\u20131547. \n                    https:\/\/doi.org\/10.1177\/0269881110378370","journal-title":"J Psychopharmacol"},{"key":"5238_CR13","doi-asserted-by":"publisher","unstructured":"Burns L, Roxburgh A, Matthews A, Bruno R, Lenton S, Van Buskirk J (2014) The rise of new psychoactive substance use in Australia. Drug Test Anal 6(7\u20138):846\u2013849. \n                    https:\/\/doi.org\/10.1002\/dta.1626","DOI":"10.1002\/dta.1626"},{"key":"5238_CR14","unstructured":"Bush DM, Woodwell DA (2013) Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ Report"},{"key":"5238_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12\u201341. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.08.005","journal-title":"Drug Alcohol Depend"},{"key":"5238_CR16","doi-asserted-by":"publisher","unstructured":"Caudevilla-G\u00e1lligo F, Riba J, Ventura M, Gonz\u00e1lez D, Farr\u00e9 M, Barbanoj MJ, Bouso JC (2012) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 26(7):1026\u20131035. \n                    https:\/\/doi.org\/10.1177\/0269881111431752","DOI":"10.1177\/0269881111431752"},{"issue":"4","key":"5238_CR17","doi-asserted-by":"publisher","first-page":"e20162675","DOI":"10.1542\/peds.2016-2675","volume":"139","author":"HB Clayton","year":"2017","unstructured":"Clayton HB, Lowry R, Ashley C, Wolkin A, Grant AM (2017) Health risk behaviors with synthetic cannabinoids versus marijuana. Pediatrics 139(4):e20162675","journal-title":"Pediatrics"},{"issue":"9","key":"5238_CR18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.clinthera.2018.08.002","volume":"40","author":"MA Luca De","year":"2018","unstructured":"De Luca MA, Fattore L (2018) Therapeutic use of synthetic cannabinoids: still an open issue? Clin Ther 40(9):1457\u20131466. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.002","journal-title":"Clin Ther"},{"key":"5238_CR19","unstructured":"Derogatis LR (1993) Brief Symptom Inventory: BSI; administration, scoring, and procedures manual. Pearson"},{"issue":"3","key":"5238_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Forti Di","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M et al (2015) Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2(3):233\u2013238. \n                    https:\/\/doi.org\/10.1016\/S2215-0366(14)00117-5","journal-title":"Lancet Psychiatry"},{"key":"5238_CR21","doi-asserted-by":"publisher","unstructured":"Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I et al (2015) Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila) 53(9):893\u2013900. \n                    https:\/\/doi.org\/10.3109\/15563650.2015.1088157","DOI":"10.3109\/15563650.2015.1088157"},{"issue":"1","key":"5238_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lfs.2013.12.212","volume":"97","author":"MA ElSohly","year":"2014","unstructured":"ElSohly MA, Gul W, Wanas AS, Radwan MM (2014) Synthetic cannabinoids: analysis and metabolites. Life Sci 97(1):78\u201390. \n                    https:\/\/doi.org\/10.1016\/j.lfs.2013.12.212","journal-title":"Life Sci"},{"key":"5238_CR23","doi-asserted-by":"publisher","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2015) New psychoactive substances in Europe. Lisbon. \n                    https:\/\/doi.org\/10.2810\/372415","DOI":"10.2810\/372415"},{"key":"5238_CR24","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2017) Perspectives on drugs: synthetic cannabinoids in Europe"},{"issue":"7","key":"5238_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.biopsych.2016.02.001","volume":"79","author":"L Fattore","year":"2016","unstructured":"Fattore L (2016) Synthetic cannabinoids\u2014further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 79(7):539\u2013548. \n                    https:\/\/doi.org\/10.1016\/j.biopsych.2016.02.001","journal-title":"Biol Psychiatry"},{"issue":"6","key":"5238_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","volume":"18","author":"PJ Gates","year":"2014","unstructured":"Gates PJ, Albertella L, Copeland J (2014) The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev 18(6):477\u2013487. \n                    https:\/\/doi.org\/10.1016\/j.smrv.2014.02.005","journal-title":"Sleep Med Rev"},{"issue":"1","key":"5238_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08897077.2015.1023484","volume":"37","author":"P Gates","year":"2016","unstructured":"Gates P, Albertella L, Copeland J (2016) Cannabis withdrawal and sleep: a systematic review of human studies. Subst Abus 37(1):255\u2013269. \n                    https:\/\/doi.org\/10.1080\/08897077.2015.1023484","journal-title":"Subst Abus"},{"key":"5238_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jad.2014.09.016","volume":"171","author":"M Gibbs","year":"2015","unstructured":"Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP (2015) Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 171:39\u201347. \n                    https:\/\/doi.org\/10.1016\/j.jad.2014.09.016","journal-title":"J Affect Disord"},{"issue":"9698","key":"5238_CR29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(09)61037-0","volume":"374","author":"W Hall","year":"2009","unstructured":"Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet (London, England) 374(9698):1383\u20131391. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)61037-0","journal-title":"Lancet (London, England)"},{"issue":"2","key":"5238_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/npp.2015.251","volume":"41","author":"M Haney","year":"2016","unstructured":"Haney M, Evins AE (2016) Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology 41(2):393\u2013401. \n                    https:\/\/doi.org\/10.1038\/npp.2015.251","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"5238_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2006.05.002","volume":"95","author":"C Henquet","year":"2006","unstructured":"Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J (2006) Cannabis use and expression of mania in the general population. J Affect Disord 95(1\u20133):103\u2013110. \n                    https:\/\/doi.org\/10.1016\/j.jad.2006.05.002","journal-title":"J Affect Disord"},{"issue":"January 2005","key":"5238_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsat.2015.01.008","volume":"53","author":"M Hildebrand","year":"2015","unstructured":"Hildebrand M (2015) The psychometric properties of the drug use disorders identification test (DUDIT): a review of recent research. J Subst Abus Treat 53(January 2005):52\u201359. \n                    https:\/\/doi.org\/10.1016\/j.jsat.2015.01.008","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"5238_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/adb.12334","volume":"22","author":"AF Hoffman","year":"2017","unstructured":"Hoffman AF, Lycas MD, Kaczmarzyk JR, Spivak CE, Baumann MH, Lupica CR (2017) Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid \u201cspice\u201d compounds: comparison with \u0394(9)-tetrahydrocannabinol. Addict Biol 22(2):390\u2013399. \n                    https:\/\/doi.org\/10.1111\/adb.12334","journal-title":"Addict Biol"},{"issue":"January","key":"5238_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugalcdep.2014.11.033","volume":"147","author":"L Hondebrink","year":"2015","unstructured":"Hondebrink L, Nugteren-van Lonkhuyzen JJ, van der Gouwe D, Brunt TM (2015) Monitoring new psychoactive substances (NPS) in the Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend 147(January):109\u2013115. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.11.033","journal-title":"Drug Alcohol Depend"},{"issue":"20","key":"5238_CR35","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1021\/jm960394y","volume":"39","author":"JW Huffman","year":"1996","unstructured":"Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39(20):3875\u20133877","journal-title":"J Med Chem"},{"issue":"22","key":"5238_CR36","first-page":"618","volume":"64","author":"R Law","year":"2015","unstructured":"Law R, Schier J, Martin C, Chang A, Wolkin A, Centers for Disease Control (CDC) (2015) Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use\u2014United States, January\u2013May 2015. Morb Mortal Wkly Rep 64(22):618\u2013619","journal-title":"Morb Mortal Wkly Rep"},{"issue":"5","key":"5238_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2174\/1871527316666170413101839","volume":"16","author":"G Martinotti","year":"2017","unstructured":"Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O (2017) Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets 16(5):567\u2013575. \n                    https:\/\/doi.org\/10.2174\/1871527316666170413101839","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"5238_CR38","doi-asserted-by":"publisher","unstructured":"Miliano C, Margiani G, Fattore L, De Luca MA (2018) Sales and advertising channels of new psychoactive substances (NPS): internet, social networks, and smartphone apps. Brain Sci 8(7). \n                    https:\/\/doi.org\/10.3390\/brainsci8070123","DOI":"10.3390\/brainsci8070123"},{"key":"5238_CR39","doi-asserted-by":"publisher","unstructured":"Miller ET, Neal DJ, Roberts LJ, Baer JS, Cressler SO, Metrik J, Marlatt GA (2002) Test-retest reliability of alcohol measures: is there a difference between internet-based assessment and traditional methods? Psychol Addict Behav 16(1):56\u201363. \n                    https:\/\/doi.org\/10.1037\/0893-164X.16.1.56","DOI":"10.1037\/0893-164X.16.1.56"},{"issue":"9584","key":"5238_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","volume":"370","author":"THM Moore","year":"2007","unstructured":"Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (London, England) 370(9584):319\u2013328. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61162-3","journal-title":"Lancet (London, England)"},{"issue":"5","key":"5238_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","volume":"34","author":"CM Morin","year":"2011","unstructured":"Morin CM, Belleville G, B\u00e9langer L, Ivers H (2011) The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 34(5):601\u2013608. \n                    https:\/\/doi.org\/10.1093\/sleep\/34.5.601","journal-title":"Sleep"},{"key":"5238_CR42","doi-asserted-by":"publisher","unstructured":"Muller C, Morales P, Reggio PH (2019) Cannabinoid ligands targeting TRP channels. Front Mol Neurosci, 11(487). \n                    https:\/\/doi.org\/10.3389\/fnmol.2018.00487","DOI":"10.3389\/fnmol.2018.00487"},{"key":"5238_CR43","doi-asserted-by":"publisher","unstructured":"Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M (2016) Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 15(3):195\u2013204. \n                    https:\/\/doi.org\/10.1002\/wps.20341","DOI":"10.1002\/wps.20341"},{"issue":"1","key":"5238_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00414-013-0864-1","volume":"128","author":"F Musshoff","year":"2014","unstructured":"Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auw\u00e4rter V (2014) Driving under the influence of synthetic cannabinoids (\u201cspice\u201d): a case series. Int J Legal Med 128(1):59\u201364. \n                    https:\/\/doi.org\/10.1007\/s00414-013-0864-1","journal-title":"Int J Legal Med"},{"key":"5238_CR45","doi-asserted-by":"publisher","unstructured":"Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30(Suppl 1):S13\u2013S18. \n                    https:\/\/doi.org\/10.1038\/sj.ijo.0803272","DOI":"10.1038\/sj.ijo.0803272"},{"issue":"10","key":"5238_CR46","first-page":"1351","volume":"31","author":"BM Roane","year":"2008","unstructured":"Roane BM, Taylor DJ (2008) Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep 31(10):1351\u20131356","journal-title":"Sleep"},{"issue":"1","key":"5238_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20174","volume":"14","author":"F Schifano","year":"2015","unstructured":"Schifano F, Orsolini L, Duccio Papanti G, Corkery JM (2015) Novel psychoactive substances of interest for psychiatry. World Psychiatry 14(1):15\u201326. \n                    https:\/\/doi.org\/10.1002\/wps.20174","journal-title":"World Psychiatry"},{"key":"5238_CR48","doi-asserted-by":"publisher","unstructured":"Shalit N, Barzilay R, Shoval G, Shlosberg D, Mor N, Zweigenhaft N, Weizman A, Krivoy A (2016) Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: a comparative study. J Clin Psychiatry 77(8):e989\u2013e995. \n                    https:\/\/doi.org\/10.4088\/JCP.15m09938","DOI":"10.4088\/JCP.15m09938"},{"issue":"21","key":"5238_CR49","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1007\/s00216-015-8612-7","volume":"407","author":"V Shevyrin","year":"2015","unstructured":"Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (2015) Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group. Anal Bioanal Chem 407(21):6301\u20136315. \n                    https:\/\/doi.org\/10.1007\/s00216-015-8612-7","journal-title":"Anal Bioanal Chem"},{"key":"5238_CR50","doi-asserted-by":"publisher","unstructured":"Soh YNA, Elliott S (2014) An investigation of the stability of emerging new psychoactive substances. Drug Test Anal 6(7\u20138):696\u2013704. \n                    https:\/\/doi.org\/10.1002\/dta.1576","DOI":"10.1002\/dta.1576"},{"issue":"2","key":"5238_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2478\/nsad-2014-0016","volume":"31","author":"C Soussan","year":"2014","unstructured":"Soussan C, Kjellgren A (2014) The flip side of \u201cspice\u201d: the adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. Nordic Stud Alcohol Drugs 31(2):207\u2013220. \n                    https:\/\/doi.org\/10.2478\/nsad-2014-0016","journal-title":"Nordic Stud Alcohol Drugs"},{"issue":"1","key":"5238_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archpsyc.64.1.57","volume":"64","author":"SM Strakowski","year":"2007","unstructured":"Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Arnold LM, Amicone J (2007) Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 64(1):57\u201364. \n                    https:\/\/doi.org\/10.1001\/archpsyc.64.1.57","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"5238_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2016","unstructured":"Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 54(1):1\u201313. \n                    https:\/\/doi.org\/10.3109\/15563650.2015.1110590","journal-title":"Clin Toxicol"},{"key":"5238_CR54","unstructured":"United Nations Office on Drugs and Crime. (2017) World Drug Report 2017"},{"key":"5238_CR55","doi-asserted-by":"publisher","unstructured":"van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29(3):254\u2013263. \n                    https:\/\/doi.org\/10.1177\/0269881114565142","DOI":"10.1177\/0269881114565142"},{"issue":"1","key":"5238_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/mp.2016.21","volume":"22","author":"E Giessen van de","year":"2017","unstructured":"van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Abi-Dargham A (2017) Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry 22(1):68\u201375. \n                    https:\/\/doi.org\/10.1038\/mp.2016.21","journal-title":"Mol Psychiatry"},{"issue":"1\u20133","key":"5238_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","volume":"120","author":"R Vandrey","year":"2012","unstructured":"Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend 120(1\u20133):238\u2013241. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.07.011","journal-title":"Drug Alcohol Depend"},{"issue":"23","key":"5238_CR58","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Baler RD, Compton WM, Weiss SRB (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219\u20132227. \n                    https:\/\/doi.org\/10.1056\/NEJMra1402309","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"5238_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","volume":"131","author":"AR Winstock","year":"2013","unstructured":"Winstock AR, Barratt MJ (2013) Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131(1\u20133):106\u2013111. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.12.011","journal-title":"Drug Alcohol Depend"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05238-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T23:04:41Z","timestamp":1586300681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05238-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["5238"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05238-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}